Clinical trial
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
NCT02833948 is registered in ClinicalTrials.gov with ECRI bv as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
- Lead sponsor
- ECRI bv
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2016
- Completion date
- March 6, 2019
- Enrollment
- 231 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.